Gene Therapy Zynteglo denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gene therapy zynteglo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Zynteglo as Experimental — and Why You Can Appeal

Blue Cross Blue Shield occasionally issues experimental or investigational denials for advanced therapies even after FDA approval. For Zynteglo (betibeglogene spartacus), this denial is typically unsustainable because the FDA granted regular approval for the treatment of transfusion-dependent beta-thalassemia in adults and pediatric patients. An experimental denial for an FDA-approved therapy must be rebutted with the approval status and the body of published clinical evidence supporting that approval.

## Why This Denial Is Appealable

Under most BCBS plan documents, a therapy cannot be classified as experimental if it holds full FDA approval for the indication being treated. The appeal argument is straightforward: cite the FDA approval, cite the relevant professional society recommendations (such as those from the applicable hematology guideline organization), and demonstrate that the denial was based on an outdated or incorrect classification.

## Federal Appeal Framework

• Internal appeal (Level 1): File under ACA §2719 and ERISA §503 within the timeframe stated on your denial letter. BCBS must issue a decision within 30 days (pre-service) or 60 days (post-service).
• External review: After exhausting internal appeal, request IRO review under ACA §2719. The window to request external review is typically 4 months from the final adverse benefit determination — confirm the exact date on your denial notice.
• Expedited option: If waiting poses a serious health risk, request simultaneous expedited internal and external review; decisions are due within 72 hours.

## Documentation to Gather

1. FDA approval evidence: A printout or reference to the FDA's official approval record for Zynteglo, including the approved indication, sourced from FDA.gov. 2. Prescribing label: The current FDA-approved prescribing information confirming approved use for beta-thalassemia. 3. Diagnosis confirmation: Genetic and clinical records confirming transfusion-dependent beta-thalassemia and that your patient meets the approved indication. 4. Professional society support: Citations from the applicable hematology/oncology guideline organization endorsing gene therapy for this condition. 5. Prescriber medical-necessity letter: Your hematologist's letter explaining that Zynteglo is an FDA-approved, guideline-consistent, medically necessary treatment — not experimental.

## Criteria-Mapping Structure

Obtain BCBS's written experimental/investigational policy definition. Most plans use criteria such as: FDA approval status; sufficient clinical evidence in peer-reviewed literature; endorsement by a national professional medical organization. Map each criterion to the evidence:

| Experimental Criterion | Rebuttal Evidence | |---|---| | FDA approval for the indication | [FDA.gov approval reference for beta-thalassemia indication] | | Published peer-reviewed clinical evidence | [Citations from hematology literature, per prescriber letter] | | Professional society endorsement | [Relevant guideline organization recommendation] |

Include a clear cover letter stating that denial of an FDA-approved therapy on experimental grounds is legally and clinically unsupported, and request that the plan reconsider under its own experimental-coverage policy criteria.